Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 749-755

  Min, Le ^a   Hodi, Frank Stephen ^b   Giobbie Hurder, Anita ^b   Ott, Patrick A ^b   Luke, Jason J ^b,c   Donahue, Hilary ^b   Davis, Meredith ^b   Carroll, Rona S ^a   Kaiser, Ursula B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; IPILIMUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADRENAL INSUFFICIENCY; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPONATREMIA; HYPOPHYSIS DISEASE; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PITUITARY ENLARGEMENT; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; TREATMENT DURATION; ADULT; AGED; CHEMICALLY INDUCED; COHORT ANALYSIS; KAPLAN MEIER METHOD; MELANOMA; MIDDLE AGED; MORTALITY; PITUITARY DISEASES;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PITUITARY DISEASES; RETROSPECTIVE STUDIES;

EID: 84923186196     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2353     Document Type: Article

References (27)

1. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
5. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-8.
6. Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 2012;18:351-5.
7. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99:4078-85.
8. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.
9. Weber JS. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ Book 2012;32:174-7.
10. Corsello SM, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, Torino F. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol 2013;72:489-90.
11. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8.
12. Beck KE, Blans fi eld JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24: 2283-9.
13. Margolin K, Ernstoff MS, Hamid O, Lawrence D,McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-65.
14. Johannsson G, Falorni A, Skrtic S, Lennernas H,QuinklerM,MonsonJP, et al. Adrenal insufficiency: reviewof clinicaloutcomeswith current glucocorticoid replacement therapy. Clin Endocrinol 2014 Sep 4. [Epub ahead of print].
15. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013;98:1361-75.
16. Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013;119:1675-82.
17. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2009;13: 29-38.
18. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014;6: 230ra45.
19. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, Rose NR. Autoimmune hypophysitis. Endocr Rev 2005;26:599-614.
20. Hamnvik OP, Laury AR, Laws ER Jr, Kaiser UB. Lymphocytic hypophysitis with diabetes insipidus in a young man. Nat Rev Endocrinol 2010;6: 464-70.
21. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
22. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiationinduced hypopituitarism. Endocr Relat Cancer 2009;16:733-72.
23. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 2009;5:88-99.
24. Buxton N, Robertson I. Lymphocytic and granulocytic hypophysitis: a single centre experience. Br J Neurosurg 2001;15:242-5.
25. Kristof RA, Van Roost D, Klingmuller D, Springer W, Schramm J. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? J Neurol Neurosurg Psychiatry 1999; 67:398-402.
26. Dinsen S, Baslund B, Klose M, Rasmussen AK, Friis-Hansen L, Hilsted L, et al. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 2013;24:714-20.
27. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014;312:1744-53.